Phase 3 Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival in Radioiodine-Refractory Differentiated Thyroid Cancer

By February 4, 2014Corporate News

Woodcliff Lake, NJ, February 2, 2014 – Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Read More… (PDF File, 75 KB)